A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

Weill, David; Benden, Christian; Corris, Paul A.; Dark, John H.; Davis, Robert D.; Keshavjee, Shaf; Lederer, David J.; Mulligan, Michael J.; Patterson, G. Alexander; Singer, Lianne G.; Snell, Greg; Verleden, Geert M.; Zamora, Martin R.; Glanville, Allan R.

doi:10.1016/j.healun.2014.06.014

Cited by 1,199 publications

(1,026 citation statements)

References 92 publications

Supporting

Mentioning

962

Contrasting

Unclassified

Order By: Relevance

“…Lung transplantation is performed in chronic, end‐stage lung disease patients who are at high risk of death (>50%) within 2 years without transplantation 22. These chronic diseases considerably reduce the patients’ HRQoL.…”

Section: Discussionmentioning

confidence: 99%

Patient-reported health outcomes in long-term lung transplantation survivors: A prospective cohort study

Parizi

Krabbe

Verschuuren

et al. 2018

American Journal of Transplantation

View full text Add to dashboard Cite

During the last three decades lung transplantation (LTx) has become a proven modality for increasing both survival and health‐related quality of life (HRQoL) in patients with various end‐stage lung diseases. Most previous studies have reported improved HRQoL shortly after LTx. With regard to long‐term effects on HRQoL, however, the evidence is less solid. This prospective cohort study was started with 828 patients who were on the waiting list for LTx. Then, in a longitudinal follow‐up, 370 post‐LTx patients were evaluated annually for up to 15 years. For all wait‐listed and follow‐up patients, the following four HRQoL instruments were administered: State‐Trait Anxiety Inventory, Zung Self‐rating Depression Scale, Nottingham Health Profile, and a visual analogue scale. Cross‐sectional and generalized estimating equation (GEE) analysis for repeated measures were performed to assess changes in HRQoL during follow‐up. After LTx, patients showed improvement in all HRQoL domains except pain, which remained steady throughout the long‐term follow‐up. The level of anxiety and depressive symptoms decreased significantly and remained constant. In conclusion, this study showed that HRQoL improves after LTx and tends to remain relatively constant for the entire life span.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient-reported health outcomes in long-term lung transplantation survivors: A prospective cohort study

Parizi

Krabbe

Verschuuren

et al. 2018

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…33 In the most recent update of the guidelines for the selection of transplant candidates, The International Society for Heart & Lung Transplantation stated, ''carefully selected candidates with (scleroderma) can undergo successful lung transplantation.'' 34 Ultimately, the decision regarding transplant candidacy must be made on a case-by-case basis, taking into consideration the severity of lung disease and the concomitant comorbidities.…”

Section: Scleroderma and Esophageal Dysmotility In Lung Transplantatimentioning

confidence: 99%

The Intersection of GERD, Aspiration, and Lung Transplantation

Patti

Vela

Odell

et al. 2016

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophageal reflux disease (GERD) to IPF and lung transplant outcome, the American Gastroenterological Association convened during the DDW in Washington in May 2015 a multidisciplinary group of experts in the field of GERD and lung transplantation to make considerations about the care of these patients based on available data and subsequent expert panel discussion at this symposium. The following topics were discussed: (1) pathophysiology of GERD-induced pulmonary symptoms, (2) GERD evaluation before and after lung transplantation, (3) outcome of lung transplantation for IPF and scleroderma, and (4) role of laparoscopic fundoplication before or after lung transplantation.

show abstract

“…Patients with a history of malignant disease within the prior 2 to 5 years are generally not eligible for pulmonary transplantation, but should be evaluated individually taking into account tumour histology, staging and adequate treatment received (8). Interestingly, the very first human lung transplantation by Hardy and associates in 1963 was in a patient with respiratory failure related to advanced bronchial carcinoma (9).…”

Section: Primary Lung Cancermentioning

confidence: 99%

“…Rigorous pre-transplant screening to rule out unknown malignancies is mandatory in all candidates prior to listing (8). However, pre-transplant lung cancer diagnosis is not always obvious in these patients often presenting with lung infiltrates or indeterminate pulmonary nodules on chest CT scan.…”

Section: Primary Lung Cancermentioning

confidence: 99%

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Raemdonck¹,

Vos²,

Yserbyt³

et al. 2016

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

Lung transplantation is an effective and safe therapy for carefully selected patients suffering from a variety of end-stage pulmonary diseases. Lung cancer negatively affects prognosis, particularly in patients who are no longer candidates for complete resection. Lung transplantation can be considered for carefully selected and well staged lung cancer patients with proven, lung-limited, multifocal, (minimally invasive) adenocarcinoma in situ (AIS) (previously called bronchioloalveolar cell carcinoma) causing respiratory failure. Despite a substantial risk of tumour recurrence (33-75%), lung transplantation may offer a survival benefit (50% at 5 years) with best palliation of their disease. Reports on lung transplantation for other low-grade malignancies are rare. Lung transplant candidates at higher risk for developing lung cancer [mainly previous smokers with chronic obstructive lung disease (COPD) and idiopathic pulmonary fibrosis (IPF) or older patients] should be thoroughly and repeatedly screened for lung cancer prior to listing, and preferably also during waiting list time if longer than 1 year, including the use of PET-CT scan and EBUS-assisted bronchoscopy in case of undefined, but suspicious pulmonary abnormalities. Double-lung transplantation should now replace single-lung transplantation in these high-risk patients because of a 6-9% prevalence of lung cancer developing in the remaining native lung. Patients with unexpected, early stage bronchial carcinoma in the explanted lung may have favourable survival without recurrence. Early PET-CT (at 3-6 months) following lung transplantation is advisable to detect early, subclinical disease progression. Donor lungs from (former) smokers should be well examined at retrieval. Suspicious nodules should be biopsied to avoid grafting cancer in the recipient. Close follow-up with regular visits and screening test in all recipients is needed because of the increased risk of developing a primary or secondary cancer in the allograft from either donor or recipient origin.

show abstract

A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

Cited by 1,199 publications

References 92 publications

Patient-reported health outcomes in long-term lung transplantation survivors: A prospective cohort study

Patient-reported health outcomes in long-term lung transplantation survivors: A prospective cohort study

The Intersection of GERD, Aspiration, and Lung Transplantation

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Contact Info

Product

Resources

About